FTC's Prevagen Complaint Revived: Court Says 'Deceptive' Ad Allegation Plausible

District court erred in dismissing FTC complaint that Prevagen marketer Quincy Biosciences used deceptive representations in ads, Second Circuit says in long-awaited order. FTC and New York attorney general, along with advocacy group TINA, criticize Quincy's post hoc data analyses finding "false positives."